MicroRNA‑4500 suppresses tumor progression in non‑small cell lung cancer by regulating STAT3

Li,Zhi‑Ying; Zhang,Zi‑Zhou; Bi,Hui; Zhang,Qiu‑Di; Zhang,Su‑Juan; Zhou,Lin; Zhu,Xiao‑Qin; Zhou,Jun

doi:10.3892/mmr.2019.10737

MicroRNA‑4500 suppresses tumor progression in non‑small cell lung cancer by regulating STAT3

Authors:
- Zhi‑Ying Li
- Zi‑Zhou Zhang
- Hui Bi
- Qiu‑Di Zhang
- Su‑Juan Zhang
- Lin Zhou
- Xiao‑Qin Zhu
- Jun Zhou
View Affiliations

Affiliations: Department of Respiratory Medicine, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China, Department of Respiratory Medicine, The Seventh People's Hospital of Changzhou, Changzhou, Jiangsu 213011, P.R. China
Published online on: October 11, 2019 https://doi.org/10.3892/mmr.2019.10737
Pages: 4973-4983
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Research has revealed that microRNA (miR)‑4500 is downregulated in non‑small cell lung cancer (NSCLC), and miR‑4500 suppresses tumor growth by targeting lin‑28 homolog B and NRAS proto‑oncogene, GTPase. In the present study, it was reported that signal transducer and activator of transcription 3 (STAT3) may function as a novel target gene for miR‑4500 in NSCLC. The experiments conducted in the present study confirmed that the miR‑4500 expression was decreased in NSCLC tissues and cells compared with adjacent normal tissues and a normal lung cell line. miR‑4500 suppressed the cell proliferation, migration, invasion and promoted apoptosis of the human NSCLC cell lines A549 and H1975. Expression of STAT3 was negatively correlated with miR‑4500 expression in vivo. A luciferase reporter assay suggested that miR‑4500 directly targeted the 3' untranslated region of STAT3. The tumor inhibition effect of small interfering RNA STAT3 in A549 and H1975 lines may be partially impaired by a miR‑4500 inhibitor. The results of the present study suggests that miR‑4500 may be a tumor suppressor and a potential therapeutic target in NSCLC.

View Figures

View References

1	Inamura K: Lung Cancer: Understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 7:1932017. View Article : Google Scholar : PubMed/NCBI
2	McIntyre A and Ganti AK: Lung cancer-A global perspective. J Surg Oncol. 115:550–554. 2017. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
4	Deng S, Calin GA, Croce CM, Coukos G and Zhang L: Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 7:2643–2646. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
6	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fang C, Chen YX, Wu NY, Yin JY, Li XP, Huang HS, Zhang W, Zhou HH and Liu ZQ: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 7:403842017. View Article : Google Scholar : PubMed/NCBI
8	Li T, Ding ZL, Zheng YL and Wang W: MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI
9	Lin L, Tu HB, Wu L, Liu M and Jiang GN: MicroRNA-21 regulates non-small cell lung cancer cell invasion and chemo-sensitivity through SMAD7. Cell Physiol Biochem. 38:2152–2162. 2016. View Article : Google Scholar : PubMed/NCBI
10	Yin J, Wang M, Jin C and Qi Q: miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett. 7:461–465. 2014. View Article : Google Scholar : PubMed/NCBI
11	Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, et al: Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 116:e118–e127. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhang L, Qian J, Qiang Y, Huang H, Wang C, Li D and Xu B: Down-regulation of miR-4500 promoted non-small cell lung cancer growth. Cell Physiol Biochem. 34:1166–1174. 2014. View Article : Google Scholar : PubMed/NCBI
13	Lin Q, Zheng H, Xu J, Zhang F and Pan H: LncRNA SNHG16 aggravates tumorigenesis and development of hepatocellular carcinoma by sponging miR-4500 and targeting STAT3. J Cell Biochem. Feb 18–2019.(Epub ahead of print) Doi: 10.1002/jcb.28440.
14	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
15	Harada D, Takigawa N and Kiura K: The role of STAT3 in non-small cell lung cancer. Cancers (Basel). 6:708–722. 2014. View Article : Google Scholar : PubMed/NCBI
16	Liu J, Fei D, Xing J and Du J: MicroRNA-29a inhibits proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by repressing STAT3. Biomed Pharmacother. 96:173–181. 2017. View Article : Google Scholar : PubMed/NCBI
17	Shan D, Shang Y and Hu T: MicroRNA-411 inhibits cervical cancer progression by directly targeting STAT3. Oncol Res. 27:349–358. 2019. View Article : Google Scholar : PubMed/NCBI
18	Sun CC, Li SJ, Zhang F, Zhang YD, Zuo ZY, Xi YY, Wang L and Li DJ: The novel miR-9600 suppresses tumor progression and promotes paclitaxel sensitivity in non-small-cell lung cancer through altering STAT3 expression. Mol Ther Nucleic Acids. 5:e3872016. View Article : Google Scholar : PubMed/NCBI
19	Haghikia A, Hoch M, Stapel B and Hilfiker-Kleiner D: STAT3 regulation of and by microRNAs in development and disease. JAKSTAT. 1:143–150. 2012.PubMed/NCBI
20	Carraro G, El-Hashash A, Guidolin D, Tiozzo C, Turcatel G, Young BM, De Langhe SP, Bellusci S, Shi W, Parnigotto PP and Warburton D: miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution. Dev Biol. 333:238–250. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wan LY, Woo CS, Turner PC, Wan JM and El-Nezami H: Individual and combined effects of Fusarium toxins on the mRNA expression of pro-inflammatory cytokines in swine jejunal epithelial cells. Toxicol Lett. 220:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
22	Koller D and Friedman N: Probabilistic Graphical Models: Principles and techniques-adaptive computation and machine learning. Probabilistic graphical models-principles and techniques. 2009.
23	Du WW, Ling F, Li M, Yang X, Liang Y, Peng C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, et al: MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 126:1440–1453. 2013. View Article : Google Scholar : PubMed/NCBI
24	Li S, Li Z, Guo F, Qin X, Liu B, Lei Z, Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
25	Hong L, Han Y, Zhang H, Zhao Q and Qiao Y: miR-210: A therapeutic target in cancer. Expert Opin Ther Targets. 17:21–28. 2013. View Article : Google Scholar : PubMed/NCBI
26	Xia B, Li H, Yang S, Liu T and Lou G: MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wang C, Chen Q, Li S, Li S, Zhao Z, Gao H, Wang X, Li B, Zhang W, Yuan Y, et al: Dual inhibition of PCDH9 expression by miR-215-5p up-regulation in gliomas. Oncotarget. 8:10287–10297. 2017.PubMed/NCBI
28	Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G and Tommasi S: MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget. 6:471–483. 2015. View Article : Google Scholar : PubMed/NCBI
29	Xu HY, Wang Y, Zhang H and Xu J: The long non-coding RNA UCA1, as a prognostic biomarker for high grade serous ovarian carcinoma. Eur J Gynaecol Oncol. 38:883–889. 2017.
30	Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
31	Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
32	Yu FY, Tu Y, Deng Y, Guo C, Ning J, Zhu Y, Lv X and Ye H: MiR-4500 is epigenetically downregulated in colorectal cancer and functions as a novel tumor suppressor by regulating HMGA2. Cancer Biol Ther. 17:1149–1157. 2016. View Article : Google Scholar : PubMed/NCBI
33	Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
34	Alvarez JV, Greulich H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
35	Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ and Mackeigan JP: STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 7:e308202012. View Article : Google Scholar : PubMed/NCBI
36	Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
37	Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang X: Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI
38	You S, Li R, Park D, Xie M, Sica GL, Cao Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616. 2014. View Article : Google Scholar : PubMed/NCBI
39	Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, et al: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 107:351–362. 2001. View Article : Google Scholar : PubMed/NCBI
40	Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, Horvath CM and Ronai Z: Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell. 7:517–528. 2001. View Article : Google Scholar : PubMed/NCBI